Cover Image
市場調查報告書

腦瘤、中樞神經系統腫瘤:主要19個市場的預測 2016-2026年

Brain & CNS Cancer Forecast in 19 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 358721
出版日期 內容資訊 英文 66 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
腦瘤、中樞神經系統腫瘤:主要19個市場的預測 2016-2026年 Brain & CNS Cancer Forecast in 19 Major Markets 2016-2026
出版日期: 2016年06月01日 內容資訊: 英文 66 Pages
簡介

原發性腦瘤及中樞神經系統 (CNS) 腫瘤,是腦、髓膜或中樞神經系統發生的原發性腫瘤的一群。腦瘤包含多形性膠質母細胞瘤 (GBM) 、腦膜瘤及星形細胞瘤,有120個種類以上。

本報告提供主要19個市場 (美國、法國、德國、義大利、西班牙、英國、土耳其、俄羅斯、印度、加拿大、澳洲、日本、中國、韓國、阿根廷、巴西、墨西哥、南非,及沙烏地阿拉伯) 的腦、CNS腫瘤的目前患者數 (性別、各年齡世代) 調查分析,目前盛行率,加上疾病概要,危險因素,疾病診斷與預後,主要的症狀和併發症等系統性資訊。

目錄

圖表

簡介

病因

危險因素和預防

疾病診斷

變異:各地區/民族

疾病預後和臨床過程

疾病相關的主要併發症/特徵

定量化患者數的手法

腦、CNS腫瘤的最大患病人數

腦、CNS腫瘤的位置、組織病理學

  • 位置
  • 神經表皮性腦瘤、CNS腫瘤的組織病理學
  • 多形性膠質母細胞瘤以及其他的腦、CNS腫瘤的種類

簡稱

相關出版

病患人數的線上資料庫

病患人數的產品

價格的線上資料、平台

參考文獻

附錄

圖表清單

目錄
Product Code: BCNS0010516

Primary brain and central nervous system (CNS) tumours (ICD-10 codes C70-C72) are a group of primary tumours arising in the brain, meninges or central nervous system. As such, this is a cluster of conditions rather than one disease per se. There are considered to be over 120 types of brain tumour including glioblastoma multiforme (GBM), meningiomas and astrocytomas.

This report provides the current incident population for Brain & CNS Cancer across 19 Major Markets (USA, France, Germany, Italy, Spain, UK, Turkey, Russia, India, Canada, Australia, Japan, China, South Korea, Argentina, Brazil, Mexico, South Africa and Saudi Arabia) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Brain & CNS Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Brain & CNS Cancer include:

  • Genetic susceptibility
  • Family history of brain & CNS cancers
  • Ionizing radiation exposure
  • Non-ionizing radiation exposure (e.g. mobile phones, electromagnetic fields)
  • Growth hormone deficiencies
  • Epilepsy & seizures

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Brain & CNS Cancer's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Brain & CNS Cancer and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Brain and CNS Cancer's incident population.
  • Identify sub-populations within Brain & CNS Cancer which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Brain & CNS Cancer patients.

Coverage

  • AR
  • AU
  • BR
  • CA
  • CN
  • FR
  • DE
  • IN
  • IT
  • JP
  • MX
  • RU
  • SA
  • ZA
  • KR
  • ES
  • TR
  • UK
  • US

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Brain & CNS Cancer Incidence
  • Location and Histopathology of Brain & CNS Cancer
    • Location of Brain & CNS Cancer
    • Histopathology of Neuroepithelial Brain & CNS Cancer
    • Glioblastoma Multiforme and Other Types of Glial Brain & CNS Cancer
  • Abbreviations and Acronyms used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Risk factors for gliomas and meningiomas
  • WHO Histologic grading for CNS tumours
  • Karnofsky Performance Scale (KPS) for functional assessment
  • Incidence of Brain & CNS Cancer, total (000s)
  • Incidence of Brain & CNS Cancer, males (000s)
  • Incidence of Brain & CNS Cancer, females (000s)
  • Location of Brain & CNS Cancer tumour, total (000s)
  • Incidence of Neuroepithelial Brain & CNS Cancer, total (000s)
  • Histopathology of neuroepithelial Brain & CNS Cancers, total (000s)
  • Incidence of Glioblastoma Multiforme and other glial cell histopathologies, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • USA Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • France Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • France Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Germany Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Germany Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Italy Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Italy Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Spain Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Spain Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • United Kingdom Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • United Kingdom Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Turkey Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Turkey Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Russia Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Russia Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • India Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • India Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Canada Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Canada Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Australia Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Australia Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Japan Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Japan Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • China Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • China Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • South Korea Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • South Korea Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Argentina Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Argentina Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Brazil Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Brazil Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Mexico Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Mexico Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • South Africa Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • South Africa Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)
  • Saudi Arabia Incidence of Brain & CNS Cancer by 5-yr age cohort, males (000s)
  • Saudi Arabia Incidence of Brain & CNS Cancer by 5-yr age cohort, females (000s)

List of Figures

  • Tumour location -- contribution by gender
  • Total Incident Brain & CNS tumours by location, males vs females
Back to Top